Summary
Vertex Pharmaceuticals Incorporated (VRTX) announced on November 19, 2020, a new share repurchase program authorized by its Board of Directors. This program allows the company to buy back up to $500.0 million of its common stock, with the authority extending through December 31, 2022. The repurchases can be executed through various methods, including open market transactions or privately negotiated deals, subject to prevailing business and market conditions, and other investment considerations.
Key Highlights
- 1Vertex Pharmaceuticals has authorized a new share repurchase program valued at up to $500.0 million.
- 2The new repurchase program is authorized through December 31, 2022.
- 3Repurchases can occur on the open market or via privately negotiated transactions, including Rule 10b5-1 plans.
- 4The company completed its previous $500.0 million share repurchase program, authorized in 2019, as of October 19, 2020.
- 5This indicates continued confidence by the Board in the company's financial health and future prospects.